Matthew P. Blischak - Jun 9, 2023 Form 4/A - Amendment Insider Report for Finch Therapeutics Group, Inc. (FNCH)

Role
Chief Executive Officer
Signature
By: /s/ Matthew P. Blischak
Stock symbol
FNCH
Transactions as of
Jun 9, 2023
Transactions value $
$0
Form type
4/A - Amendment
Date filed
6/23/2023, 04:30 PM
Date Of Original Report
Jun 9, 2023
Previous filing
Jun 9, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FNCH Stock Option (right to buy) Award $0 +963K $0.00 963K Jun 9, 2023 Common Stock 963K $0.27 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On June 9, 2023, the Reporting Person filed a Form 4, which, due to administrative error, inadvertently reported that the reported stock options were granted on June 8, 2023 with a strike price of $0.285, the closing price of the issuer's common stock on such date, and expiration date of June 7, 2033. In fact, as reported in this amendment, the reported stock options were granted on June 9, 2023 with a strike price of $0.271, the closing price of the issuer's common stock on such date, and expiration date of June 8, 2033.
F2 Twenty-five percent (25%) of the shares subject to this option shall vest on June 9, 2024, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service as of each such date.

Remarks:

The share prices and amounts reported in this Form 4 do not give effect to the issuer's 1-for-30 reverse stock split effected on June 9, 2023 subsequent to the stock option grant reported herein.